Editorial: Natural products as potential therapies for non-alcoholic fatty liver disease

Résumé

Editorial on the Research Topic Natural products as potential therapies for non-alcoholic fatty liver disease Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide with approximately 25% of the world's population being affected.Therefore, it is a critical public health problem.NAFLD can lead to further complications such as non-alcoholic steatohepatitis (NASH), cirrhosis, liver cancer, liver failure, and even cardiovascular diseases.Obesity is considered the main cause of NAFLD and the rapid increase in obesity due to the increased prevalence of a sedentary lifestyle and high consumption of fast food has led to an enormous rise in the number of patients with NAFLD.Therefore, there is an urgent need to develop new pharmacological interventions that can provide effective and safe treatment for this disease.Currently, the number of clinically approved pharmacological interventions that can be used in the management of NAFLD, its complications, and predisposing factors such as obesity is highly limited.Moreover, there are concerns regarding the efficacy and safety of the available treatments.In this context, natural products can serve as a vast platform that may provide a good alternative with comparable safety but lower costs.Also, there is an increasing effort in research of natural products which could be of vital importance for protection against and treatment of obesity, NAFLD, and associated cardiovascular complications.The results observed in these studies are promising and show high efficacy and safety for pharmacological use.The scope of this Research Topic covers these different subjects in four articles-one systematic review, two original articles, and one study protocol.In the first review article, Peng et al. published an interesting systematic review evaluating the effectiveness and safety of Chinese Herbal Medicine (CHM) for type 2 Diabetes mellitus (T2DM) with non-alcoholic fatty liver disease (NAFLD).Several electronic databases were thoroughly searched till December 2021.The authors originally assessed 783 relevant papers found with this search approach.Eighteen studies were finally included in this meta-analysis after duplicates were eliminated and many publications that did not satisfy the required standards were excluded.The 18 studies involved 1,463 patients, 733 in treatment and 730 in control groups.All these studies were randomized control trials (RCTs) carried out in China between 2010 and 2021.The study outcomes were lipid indices, liver functions, insulin, glycemic indices, and body

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0